Skip to main
OCS
OCS logo

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding AG is positioned favorably within the biopharmaceutical sector due to the strong Phase 2 ACUITY data for its candidate OCS-05 in acute optic neuritis, which has accelerated study timelines and reflects positive FDA interactions. The promising responder rates for OCS-01, with significant gains observed in visual acuity at both 6 and 12 weeks, further enhance investor confidence regarding the efficacy of their retinal therapies. Additionally, the design of upcoming PIONEER trials closely mirrors successful previous trials, potentially increasing the probability of favorable outcomes and reinforcing the company's positive trajectory in addressing critical eye care conditions.

Bears say

Oculis Holding AG's stock outlook is negatively impacted by potential delays in clinical development and regulatory approvals, which could lead to prolonged development timelines and increased operating costs. The company reported a net loss of CHF 16.9 million in 3Q25, raising concerns about its financial sustainability against a backdrop of significant market competition in the biopharmaceutical space targeting similar eye care indications. Furthermore, the efficacy and safety of its lead candidates, OCS-01, OCS-02, and OCS-05, remain uncertain, with risks associated with failed clinical trials posing a substantial threat to the company's future profitability and market position.

OCS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 5 analysts, OCS has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.